Halozyme Therapeutics, Inc. Forecasted to Earn Q3 2024 Earnings of $0.85 Per Share (NASDAQ:HALO)

Halozyme Therapeutics, Inc. (NASDAQ:HALOFree Report) – Analysts at Zacks Research dropped their Q3 2024 earnings per share estimates for Halozyme Therapeutics in a research note issued to investors on Wednesday, February 7th. Zacks Research analyst A. Chakraborty now anticipates that the biopharmaceutical company will post earnings of $0.85 per share for the quarter, down from their previous estimate of $0.87. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $2.56 per share. Zacks Research also issued estimates for Halozyme Therapeutics’ Q1 2025 earnings at $0.85 EPS, Q2 2025 earnings at $0.87 EPS and Q3 2025 earnings at $0.91 EPS.

A number of other equities research analysts have also weighed in on HALO. TheStreet lowered Halozyme Therapeutics from a “b-” rating to a “c+” rating in a research report on Monday, January 22nd. The Goldman Sachs Group dropped their target price on shares of Halozyme Therapeutics from $45.00 to $40.00 and set a “neutral” rating for the company in a research report on Thursday, January 18th. Morgan Stanley reduced their price target on shares of Halozyme Therapeutics from $61.00 to $59.00 and set an “overweight” rating on the stock in a research report on Tuesday, December 26th. HC Wainwright lowered their price objective on shares of Halozyme Therapeutics from $61.00 to $48.00 and set a “buy” rating for the company in a report on Thursday, January 18th. Finally, Benchmark reaffirmed a “buy” rating and issued a $50.00 price target on shares of Halozyme Therapeutics in a research note on Friday, January 19th. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $51.45.

Read Our Latest Report on Halozyme Therapeutics

Halozyme Therapeutics Price Performance

HALO stock opened at $35.24 on Friday. The company has a current ratio of 7.63, a quick ratio of 6.51 and a debt-to-equity ratio of 6.01. The firm’s 50-day moving average price is $36.57 and its two-hundred day moving average price is $38.48. The stock has a market capitalization of $4.66 billion, a price-to-earnings ratio of 18.74, a PEG ratio of 0.37 and a beta of 1.22. Halozyme Therapeutics has a 12-month low of $29.85 and a 12-month high of $51.45.

Halozyme Therapeutics (NASDAQ:HALOGet Free Report) last posted its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported $0.69 EPS for the quarter, beating analysts’ consensus estimates of $0.67 by $0.02. Halozyme Therapeutics had a net margin of 32.52% and a return on equity of 190.74%. The company had revenue of $216.03 million during the quarter, compared to analyst estimates of $219.47 million.

Institutional Trading of Halozyme Therapeutics

A number of institutional investors have recently made changes to their positions in HALO. Montag A & Associates Inc. purchased a new position in shares of Halozyme Therapeutics in the 2nd quarter worth $27,000. West Tower Group LLC bought a new stake in shares of Halozyme Therapeutics during the 2nd quarter valued at about $28,000. Massmutual Trust Co. FSB ADV increased its position in shares of Halozyme Therapeutics by 855.3% during the 2nd quarter. Massmutual Trust Co. FSB ADV now owns 812 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 727 shares during the last quarter. Bessemer Group Inc. increased its position in shares of Halozyme Therapeutics by 366.5% during the 2nd quarter. Bessemer Group Inc. now owns 807 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 634 shares during the last quarter. Finally, Covestor Ltd boosted its holdings in shares of Halozyme Therapeutics by 223.5% in the second quarter. Covestor Ltd now owns 922 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 637 shares during the last quarter. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Insiders Place Their Bets

In related news, SVP Michael J. Labarre sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $39.63, for a total value of $396,300.00. Following the transaction, the senior vice president now directly owns 151,911 shares of the company’s stock, valued at approximately $6,020,232.93. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Company Profile

(Get Free Report)

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Further Reading

Earnings History and Estimates for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.